News 
Market Data 
Discover
Replies to post #228841 on Avid Bioservices Inc (CDMO)
08/05/15 5:49 PM
Foundation Medicine collaboration with MSK. Now you tell me, after Foundation Medicine and MSK have been collaborating ever since May of 2013 and two years later after MSK LIKELY HAVING A PEEK INTO PATTERNS, TRENDS (FUTURE BIOMARKERS??!!), they (MSK) then decide to collaborate with Peregrine Pharmaceuticals on May 29, 2013 for what reasons? maybe more clues given Aug 11
LVHN to team up with top ranked Memorial Sloan Kettering Cancer Center in New York.
Lehigh Valley cancer patients to benefit from new Sloan Kettering-LVH pairing.
Good news for cancer patients in the Lehigh Valley
The number of clinical trials available to cancer patients at Lehigh Valley Health Network is about to increase exponentially under a new partnership between the network and Memorial Sloan Kettering Cancer Center.
LVHN and top-ranked Memorial Sloan Kettering of New York announced Tuesday that LVHN is joining the Memorial Sloan Kettering Cancer Alliance. The arrangement will allow LVHN doctors to collaborate with peers at Memorial Sloan Kettering, the world's oldest and biggest cancer research and treatment center.
"Our collaboration with MSK will save lives by bringing evidence-based, world-class standards to our entire health network," LVHN CEO Dr. Brian Nester said.
Established in 2013, the Cancer Alliance is a partnership between Memorial Sloan Kettering and oncology providers in outlying communities. In September 2014, Hartford HealthCare Cancer Institute, part of a multihospital health care system in Connecticut, became the first Alliance member. LVHN is the second.
"For more than a century, Memorial Sloan Kettering has been delivering exceptional, patient-focused cancer care and has generated the scientific discoveries necessary to further develop effective new treatments," Memorial Sloan Kettering CEO Dr. Craig Thompson said. "Today, we recognize the need to do more.
"Central to our mission is eradicating cancer, and through the MSK Cancer Alliance — and in collaboration with Lehigh Valley Health Network — we have a unique opportunity to share our knowledge and best practices with a wider patient population."
Nester and Thompson spoke at LVHN's John and Dorothy Morgan Cancer Center at the network's Cedar Crest location. More than 150 people, mostly hospital staff, gathered in the center's atrium to hear the news.
The Cancer Alliance has three main goals:
• Fostering the rapid adoption of advanced, evidence-based standards of care.
• Improving the quality of care and outcomes for patients.
• Expanding access to clinical trials and cutting-edge cancer research.
LVHN joins with Sloan Kettering to expand access to cancer clinical trials
A large crowd was assembled to hear that Memorial Sloan Kettering Cancer Center and Lehigh Valley Health Network announced today the beginning of a unique collaboration aimed at improving patient access to the latest and most effective cancer treatment advances to mark the first step in announcing their recently signed agreement for LVHN to join the Memorial Sloan Kettering Cancer Alliance Tuesday at LVHN's John & Dorothy Morgan Cancer Center in Allentown.
CHRIS KNIGHT / SPECIAL TO THE MORNING CALL
Dr. Craig B. Thompson, President and CEO of Memorial Sloan Kettering Cancer Center, talks about how Memorial Sloan Kettering Cancer Center and Lehigh Valley Health Network announced today the beginning of a unique collaboration aimed at improving patient access to the latest and most effective cancer treatment advances to mark the first step in announcing their recently signed agreement for LVHN to join the Memorial Sloan Kettering Cancer Alliance Tuesday at LVHN's John & Dorothy Morgan Cancer Center in Allentown.
According to experts, access to clinical trials has become increasingly important in recent years as research suggests the key to defeating cancer is matching individual types of the disease to the particular therapies to which they are vulnerable — a targeted rather than shotgun approach.
Participating in a clinical trial is also one way patients can make a singular, essential contribution to future patients.
LVHN is participating in about 100 cancer clinical trials, according to Dr. Suresh G. Nair, medical director of LVHN's cancer program.
The number of trials could gradually rise to 800 through Memorial Sloan Kettering's involvement, he said.
"That's the bottom line," he told an enthusiastic audience in the atrium, "providing more hope and better outcomes to our patients."
Memorial Sloan Kettering traces its roots to the New York Cancer Hospital, founded in 1884. Today it employs 14,000 physicians, scientists, nurses and other staff.
Thompson said Memorial Sloan Kettering identified LVHN as a potential partner after considering health care providers within a 250-mile radius of New York. Memorial Sloan Kettering was attracted to LVHN's strong record of conducting clinical trials, he said.
But also at work was a long history of connections between the two institutions starting in 1967 when Leonard Pool, founder of chemical company Air Products in Trexlertown, brought his wife to Memorial Sloan Kettering for lung cancer treatment.
St. Luke's and LVHN to share patient data with CVS
There, a young resident, Lawrence Levitt, took pity on Pool, whom he presumed was poor because he was sleeping in his wife's hospital room. Levitt invited Pool to his house for dinner. Only later did Levitt come to realize whom he had fed — after Pool donated $1 million to Memorial Sloan Kettering.
A few years later, Pool contributed the seed money to start LVHN's flagship campus, Lehigh Valley Hospital-Cedar Crest, to which he then recruited Levitt to work as a neurologist.
Long before he became CEO of Memorial Sloan Kettering, Thompson too did a stint at LVH. That was in the mid-1970s, during his second and third months of clinical rotation.
"We have this deep history," Thompson said, noting that even before Tuesday's announcement some of LVHN's oncologists received specialized training at Memorial Sloan Kettering.
Memorial Sloan Kettering also stands to benefit from the alliance, primarily by expanding its clinical trials to a larger patient population, allowing it to gather more information about survival, quality of life and cost of care.
"This is a two-way street," Thompson said. "We're going to learn from each other."
http://www.mcall.com/business/mc-lvhn-memorial-sloan-kettering-20150804-story.html
